Nanoscope Therapeutics Inc.
Sabrina Macias, PhD, is a highly skilled scientist with expertise in pre-clinical research and development, currently working at Nanoscope Therapeutics Inc. since February 2024. Prior experience includes a role as a scientist at Telos Biotech, where significant contributions were made to the characterization of immune cells and assay development. At evitria AG, Sabrina excelled in managing client relations and providing technical guidance for recombinant antibody production. As an Immune Engineer and Project Lead Scientist at the University of Florida, Sabrina led pre-clinical testing and developed advanced assay workflows. Additional experience includes research at Arizona State University and a summer internship at the National Institutes of Health, focusing on machine learning in biomedical imaging. Sabrina earned a PhD in Biomedical/Medical Engineering from the University of Florida and a B.S. in the same field from Arizona State University.
This person is not in any teams
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa